Genomic Deletion of Malic Enzyme 2 Linked to Pancreatic Cancer Lethality

An author correction published in the journal Nature on September 17, 2026, clarifies a significant finding regarding pancreatic cancer, identifying the genomic deletion of malic enzyme 2 (ME2) as a factor that confers collateral lethality. This correction addresses a previous publication and refines the understanding of a specific genetic alteration's role in the disease's progression and susceptibility to certain treatments.

Malic enzyme 2 is an enzyme involved in cellular metabolism, specifically in the conversion of malate to pyruvate, a process that can generate NADPH. NADPH is a crucial molecule for cellular defense against oxidative stress and for biosynthesis. In the context of cancer, metabolic alterations are common, and ME2 has been implicated in supporting cancer cell growth and survival. The identification of its genomic deletion as a cause of collateral lethality suggests that this genetic event makes pancreatic cancer cells uniquely vulnerable to specific therapeutic interventions or metabolic stresses, even as it might offer some protective benefit under normal conditions.

Collateral lethality is a concept in cancer biology where a genetic alteration that confers resistance to one type of therapy simultaneously sensitizes the cancer cells to another therapy or metabolic condition. This phenomenon is of great interest for developing novel therapeutic strategies, as it offers a way to exploit specific cancer vulnerabilities. The author correction in Nature indicates that the absence or significant reduction of ME2 due to genomic deletion creates a metabolic dependency or vulnerability in pancreatic cancer cells that can be targeted. This could involve targeting pathways that are upregulated to compensate for the loss of ME2's function or exploiting the resulting metabolic imbalance.

Pancreatic cancer is known for its aggressive nature and poor prognosis, with limited effective treatment options. Understanding the specific genetic and metabolic underpinnings of its lethality is crucial for improving patient outcomes. The clarification provided by this author correction contributes to the growing body of research aimed at dissecting the complex molecular landscape of pancreatic cancer. Further research stemming from this finding could lead to the development of targeted therapies that exploit the collateral lethality conferred by ME2 deletion, potentially offering new hope for patients with this devastating disease. The specific doi for the author correction is 10.1038/s41586-026-11134-x, published online on September 17, 2026, in Nature.